Indegene crossed the ₹1,000 crore quarterly revenue milestone in Q4 FY26 — a first in company history. FY26: revenue ₹3,511 crore (+23.6%), adjusted EBITDA ₹679 crore (19.3%), free cash flow ₹607 crore, cash ₹1,539 crore. Adjusted PAT ₹458 crore (reported ₹401 crore impacted by one-time TCPA provision). GenAI/Tectonic pilots converting to long-term pharma contracts is the FY27 catalyst. Near-term margin investment phase acknowledged. Good sentiment, medium confidence.
Headline Numbers
| Metric | FY26 / Q4 FY26 | Notes |
|---|---|---|
| Q4 Revenue | ₹1,000 crore+ | First ₹1,000 cr quarter — milestone |
| FY26 Revenue | ₹3,511 crore | +23.6% YoY |
| FY26 Adjusted EBITDA | ₹679 crore | 19.3% margin |
| FY26 Adjusted PAT | ₹458 crore | — |
| FY26 Reported PAT | ₹401 crore | Incl. TCPA provision |
| Q4 Adj EBITDA | ₹189 crore | — |
| Q4 Reported PAT | ₹80 crore | — |
| Free Cash Flow FY26 | ₹607 crore | — |
| Cash and Investments | ₹1,539 crore | — |
| Operating Cash Flow | ₹651 crore | — |
| DSO | 63 days | Debtor collection efficiency |
| TCPA Provision | ₹20.3 crore | One-time; non-recurring |
What Drove the Results
- ₹1,000 crore quarterly revenue — scale enabling enterprise contract wins: Crossing ₹1,000 crore in a single quarter means Indegene can now bid for larger enterprise-level contracts (top 20 pharma companies have procurement thresholds for global vendors). This milestone likely unlocks new client conversations that were not accessible at smaller scale.
- 23.6% YoY growth — consistent execution in a growing market: Pharma companies globally are increasing technology spend (digital transformation, GenAI adoption, regulatory efficiency). Indegene's 23.6% growth reflects: new client wins, expansion within existing clients (ARPU growth), and new service offerings (Tectonic GenAI). The 5-8% CAGR of global pharma industry provides a stable underlying demand base.
- Free cash flow ₹607 crore — high-quality earnings: FCF conversion of 90%+ of adjusted PAT indicates Indegene's revenue is cash-collecting (DSO 63 days — healthy for enterprise software services). This high FCF ratio means the reported numbers are real — no revenue recognition gaming or working capital build.
- Tectonic GenAI — the FY27 catalyst: Management's Tectonic platform (GenAI for pharma) is in pilot phase with large clients. Each pilot that converts to a 3-5 year commercial contract is meaningful: large pharma clients spend $50-200M+ annually on the processes Tectonic automates. One or two Tectonic wins would significantly accelerate FY27 revenue growth.
- Cash ₹1,539 crore + FCF ₹607 crore annually — optionality for M&A: Indegene's balance sheet strength enables acquisitions of complementary healthcare technology companies without dilution. Management has indicated interest in selective M&A at "reasonable valuations with clear path to profitability" — the cash position makes this credible.
What Management Said
Management was confident on long-term but clear about near-term investment. On Q4 milestone: "Crossing ₹1,000 crore in a quarter is significant — it reflects the scale and growth momentum of the business." On Tectonic: "We have pilots running with large pharma clients. Our confidence in Tectonic converting from pilots to long-term contracts is high." On FY27 margins: "We are investing in AI capabilities, sales, and talent. H1 FY27 margins will reflect these investments. H2 recovery as investments convert to revenue." On free cash flow: "₹607 crore free cash flow — this is a testament to the quality of our earnings. We convert profits to cash efficiently." On risk: "LLM commoditization of domain knowledge is a risk we acknowledge. Our moat is the integration of AI with regulatory knowledge and pharma workflows — not AI itself."
Key Tailwinds and Risks
Tailwinds:
- GenAI creating new pharma automation market — Indegene positioned as pharma-specific AI platform
- Large pharma spending on digital transformation (+5-8% industry growth, tech spend outpacing)
- Tectonic pilots converting to multi-year contracts in FY27
- Biotech funding recovery enabling mid-small pharma spending
- Cash ₹1,539 crore + FCF ₹607 cr — M&A optionality at attractive valuations
Risks:
- Near-term margin compression from AI/sales/talent investments in H1 FY27
- LLM commoditization — if general-purpose AI models replicate Indegene's domain workflows, moat erodes
- US regulatory/policy environment changes affecting pharma industry spending patterns
- TCPA-style litigation risk in US pharma communications compliance
- Biotech funding uncertainty affecting small/mid pharma client spending
StockMirror AI Signal Summary
| Signal | Reading |
|---|---|
| Overall Sentiment | Good |
| Management Confidence | Medium |
| Prepared Remarks | Good — ₹1,000 cr milestone, FCF strength, Tectonic opportunity |
| Q&A Sentiment | Neutral-Good — candid on margin investment phase, LLM risk acknowledged |
| Revenue Growth | Strong — 23.6% FY26, ₹1,000 cr Q4 milestone |
| Margin Direction | Pressured H1 FY27 — investment phase; H2 recovery |
| Earnings Quality | Strong — FCF ₹607 cr; DSO 63 days; adjusted PAT clean |
Track Indegene's full AI earnings breakdown — revenue growth trajectory, Tectonic GenAI progress, and margin path — at Indegene's earnings page.
Key Takeaways
- Q4 FY26: first ₹1,000 crore quarter; FY26 revenue ₹3,511 crore (+23.6%)
- Adjusted EBITDA ₹679 crore (19.3%); adjusted PAT ₹458 crore; FCF ₹607 crore
- Cash ₹1,539 crore; DSO 63 days — high-quality cash-generating business
- FY27: EBITDA margin pressure H1 (investments in AI, sales); recovery expected H2
- Tectonic GenAI pilot-to-contract conversion is the key FY27 catalyst
Frequently Asked Questions
What is Indegene's FY26 revenue and quarterly milestone? Indegene crossed the ₹1,000 crore quarterly revenue milestone in Q4 FY26. FY26 full-year revenue was ₹3,511 crore (+23.6% YoY). Adjusted EBITDA was ₹679 crore (19.3% margin) and adjusted PAT ₹458 crore. Free cash flow was ₹607 crore with cash and investments of ₹1,539 crore.
What does Indegene do for pharma companies? Indegene provides digital-driven services to life sciences companies: commercial operations (AI-powered sales force management, multichannel marketing to healthcare professionals), medical affairs (regulatory submissions, scientific communication), and digital health solutions. Its GenAI platform Tectonic automates content generation for regulatory-compliant medical materials — reducing cost and accelerating pharma company workflows.
What is Indegene's FY27 outlook? Management guided that H1 FY27 EBITDA margins will be pressured by investments in GenAI capabilities, sales force expansion, and talent. H2 FY27 margin recovery is expected as these investments convert to revenue. The key catalyst: Tectonic GenAI pilot clients converting to multi-year commercial contracts with major pharma companies.
Related: Unicommerce Q4 FY26 · Granules India Q4 FY26
Disclaimer: This article is for informational purposes only and does not constitute investment advice. StockMirror's AI analysis is based on publicly available earnings transcripts and BSE/NSE filings. Please consult a SEBI-registered financial advisor before making investment decisions.